A U.S. judge has allowed parts of a shareholder lawsuit against Novo Nordisk to move forward, alleging the company misled investors about the design and tolerability of its experimental weight-loss drug CagriSema. Investors claim Novo did not fully disclose that the REDEFINE-1 trial used a flexible dosing approach, which affected the drug's reported effectiveness and tolerability. The ruling does not confirm wrongdoing but permits discovery to seek evidence. This case comes as Novo faces increased competition in the obesity drug market and relies on CagriSema to strengthen its position.
Novo Resources is advancing exploration at the Tibooburra Gold Project in NSW through a joint venture with Manhattan Gold Corporation. A ~2,700 meter reverse circulation (RC) drilling program is planned to begin in late Q3 2026, focusing on the Clone...
Novo Nordisk has launched a share repurchase program to buy back B shares worth up to DKK 11.2 billion from May 2026 to February 2027, as part of a larger DKK 15 billion buyback plan starting February 2026. Since February, the company has repurchased...
Novo Nordisk is rated a Modest Buy with an increased price target of $80, driven by the rapid adoption of its oral Wegovy medication. Oral Wegovy has achieved over 3 million prescriptions within five months, with 80% of users being new to GLP-1 treat...
Novo Nordisk's stock has dropped over 30% since mid-2024 amid ongoing downtrend. Investors are focusing on the upcoming Q2 earnings report, paying close attention to management's confidence in their transformation plans rather than short-term earning...
Willow Tree Research initiates coverage of Novo Nordisk with a BUY rating and a $68 price target, citing the attractive valuation. The launch of oral Wegovy is expanding the obesity treatment market rather than just replacing injectable versions, sup...
